

You're invited to come learn about...



To register, please:

- CALL **1-877-397-9097** or
- FAX this page (fill out form below) or
- VISIT **www.meetingreply.com/purduespeakerprogram**

Please use the following unique Invitation Code when registering online:

13179 – 0000

THE FIRST BUPRENORPHINE TRANSDERMAL SYSTEM

A Purdue Pharma L.P. Speaker Program

SPEAKER: STEVEN DONATELLO, MD
MEETING DATE: 11/19/2014
MEETING TIME: 6:30 PM
VENUE: Firefly Urban Bar & Grill
VENUE ADDRESS: 7754 Harwood Avenue
Wauwatosa, WI 53213

To register by fax:

Please fax this page to: **1-212-370-1172** For questions, call: **1-877-397-9097**

☒ Yes, I will attend.

Consistent with reporting obligations, including but not limited to the Federal Physician Payment Sunshine Act, Purdue will disclose food and beverage consumed by HCPs as transfers of value. Invitees to Purdue Pharma L.P. Speaker Programs are permitted to attend the educational session and not partake in any food or beverage. Should you wish to attend and not partake in the food or beverage offering, please indicate so upon registration. Attendees are not permitted to order and pay for food and/or beverage that is not provided by Purdue.

NAME _____

ADDRESS _____

CITY _____ STATE _____ ZIP _____

PHONE _____

EMAIL _____ FAX _____

PLEASE INDICATE YOUR PROFESSIONAL DESIGNATION BY CHECKING THE APPROPRIATE BOX BELOW

☐ MD ☐ DO ☐ PA ☐ RN ☐ NP ☐ RPh ☐ PharmD ☐ Other

WARNING: ADDICTION, ABUSE and MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL EXPOSURE; and NEONATAL OPIOID WITHDRAWAL SYNDROME

Addiction, Abuse, and Misuse

Butrans exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk prior to prescribing Butrans, and monitor all patients regularly for the development of these behaviors or conditions [see *Warnings and Precautions (5.1) and Overdosage (10)*].

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of Butrans. Monitor for respiratory depression, especially during initiation of Butrans or following a dose increase. Misuse or abuse of Butrans by chewing, swallowing, snorting or injecting buprenorphine extracted from the

transdermal system will result in the uncontrolled delivery of buprenorphine and pose a significant risk of overdose and death [see *Warnings and Precautions (5.2)*].

Accidental Exposure

Accidental exposure to even one dose of Butrans, especially by children, can result in a fatal overdose of buprenorphine [see *Warnings and Precautions (5.2)*].

Neonatal Opioid Withdrawal Syndrome

Prolonged use of Butrans during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available [see *Warnings and Precautions (5.3)*].

Parentheses refer to sections in the Full Prescribing Information.

Please read accompanying Full Prescribing Information, including Boxed Warning above.

This program is intended for healthcare professionals with prescribing authority only (eg, physicians, nurse practitioners, and physician assistants). In accordance with Purdue Policy and PhRMA guidelines, spouses and guests are not permitted to attend.